All In Biotech

Drug Trial Radar · NCT06734832

Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)

A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Trial on the Efficacy, Safety, and Immunogenicity of the Bivalent Enterovirus Inactivated Vaccine (Vero Cell) in Children Aged 6 to 71 Months.

Last checked: Nov 20, 2026Latest source record: Jan 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 8,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8,000

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Nov 30, 2025

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
Dec 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 71 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-blind, controlled Phase III clinical trial aims to evaluate the efficacy, safety, and immunogenicity of the bivalent enterovirus-inactivated vaccine (Vero cell) in healthy children aged 6 to 71 months. The main questions it aims to answer are: * The primary vaccine efficacy of the investigational vaccine against Hand, Foot, and Mouth Disease(HFMD) caused by CA16 infection compared to the control vaccine. * The neutralizing antibody levels against EV71 in the trial group are non-inferior to those in the control group after two doses of vaccination. Researchers will compare the bivalent enterovirus-inactivated vaccine (Vero cell) to the EV71-inactivated vaccine (Vero cell) to prevent HFMD and Herpangina(HA). Participants will be randomly assigned to the trial group and the control group in a 1:1 ratio to receive two doses of the investigational vaccine or the control EV71 vaccine, with a one-month interval between doses.

Conditions

  • Hand, Foot, and Mouth Disease(HFMD)

Interventions

  • bivalent enterovirus vaccine (Vero cell), inactivatedBiological

    Two doses are administered with a one-month interval between each dose.

  • Enterovirus Type 71 Vaccine (Vero Cell), InactivatedBiological

    Two doses are administered with a one-month interval between each dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the primary vaccine efficacy of the trial vaccine against HFMD caused by CA16 infection compared to the control vaccine.Time frame: 1 year
  2. Evaluate whether the neutralizing antibody levels against EV71 in the trial group are non-inferior to those in the control group after two doses of vaccination.Time frame: 60 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Provincial Center for Disease Control and Prevention

    Fujian, China · Recruiting

  • Guangdong Provincial Center for Disease Control and Prevention

    Guangdong, China · Recruiting

  • Hubei Provincial Center for Disease Control and Prevention

    Hubei, China · Recruiting

  • Anhui Provincial Center for Disease Control and Prevention

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.